| Literature DB >> 27063470 |
José I López1, Peio Errarte2, Asier Erramuzpe3, Rosa Guarch4, Jesús M Cortés5, Javier C Angulo6, Rafael Pulido7, Jon Irazusta2, Roberto Llarena8, Gorka Larrinaga9.
Abstract
Clear cell renal cell carcinoma is a complex disease with only partial response to therapy and scarce reliable clinical parameters indicative of progression and survival. Fibroblast activation protein expression has been correlated with prognosis in several malignancies but never in renal cancer. We aim to analyze the immunohistochemical expression of fibroblast activation protein in 208 clear cell renal cell carcinomas and to evaluate its impact on the prognosis and survival. A positive cytoplasmic immunostaining of this protein in the stromal fibroblasts associated to cancer cells is associated with large tumor diameter (≥4cm), high-grade (G3/4) tumors, and high-stage (≥pT3) tumors. Fibroblast activation protein-positive cases had significantly shorter survivals after 5 (P=.00015), 10 (P=.0000042), and 15 (P=.000043) years of follow-up, with a hazard ratio of 0.31. Multivariate analysis showed that fibroblast activation protein (P=.00117) was stronger than grade and stage in predicting clinical aggressiveness in clear cell renal cell carcinoma. This study confirms the usefulness of fibroblast activation protein detection in the stromal fibroblast associated to cancer in clear cell renal cell carcinoma and adds a new immunohistochemical marker to predict clinical behavior in these patients.Entities:
Keywords: Clear cell renal cell carcinoma; Fibroblast activation protein; Immunohistochemistry; Prognosis; Survival
Mesh:
Substances:
Year: 2016 PMID: 27063470 DOI: 10.1016/j.humpath.2016.03.009
Source DB: PubMed Journal: Hum Pathol ISSN: 0046-8177 Impact factor: 3.466